

References

- Ahn, K., Shelton, C. C., Tian, Y., Zhang, X., Gilchrist, M. L., Sisodia, S. S., et al. (2010). Activation and intrinsic γ -secretase activity of presenilin 1. *Proceedings of the National Academy of Sciences of the United States of America*
- Ashe, K. H., et al. (2010). Probing the biology of Alzheimer's disease in mice. *Neuron*, 66, 631–645.
- Bacsikai, B. J., Hickey, G. A., Skoch, J., Kajdasz, S. T., Wang, Y., Huang, G. F., et al. (2003). Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, 100, 12462–12467.
- Ballatore, C., Lee, V. M. Y., & Trojanowski, J. Q. (2007). Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. *Nature Reviews Neuroscience*, 8, 663–672.
- Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. *Nature Medicine*, 6, 916–919.
- Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006). Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid *in vivo*. *Nature Medicine*, 12, 856–861.
- Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., et al. (2009). A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. *Annals of Neurology*, 66, 48–54.
- Bertram, L., & Tanzi, R. E. (2008). Thirty years of Alzheimer's disease genetics: The

- implications of systematic meta-analyses. *Nature Reviews. Neuroscience*, 9, 768–778.
- Bishop, N. A., Lu, T., & Yankner, B. A. (2010). Neural mechanisms of ageing and cognitive decline. *Nature*, 464, 529–535.
- Borchelt, D. R., Ratovitski, T., Van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., et al. (1997). Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. *Neuron*, 19, 939–945.
- Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitski, T., et al. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio *in vitro* and *in vivo*. *Neuron*, 17, 1005–1013.
- Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathologica*, 82, 239–259.
- Brody, D. L., & Holtzman, D. M. (2008). Active and passive immunotherapy for neurodegenerative disorders. *Annual Review of Neuroscience*, 31, 175–193.
- Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. *American Journal of Public Health*, 88, 1337–1342.
- Bu, G. (2009). Apolipoprotein E and its receptors in Alzheimer's disease: Pathways, pathogenesis and therapy 1. *Nature Reviews. Neuroscience*, 10, 333–344.
- Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain's default network: Anatomy, function, and relevance to disease 1. *Annals of the New York Academy of Sciences*, 1124, 1–38.
- Buxbaum, J. D., Thinakaran, G., Koliatsos, V., O'Callahan, J., Slunt, H. H., Price, D. L., et al. (1998). Alzheimer amyloid protein precursor in the rat

- hippocampus: Transport and processing through the perforant path. *The Journal of Neuroscience*, 18, 9629–9637.
- Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D. R., Price, D. L., et al. (2001). BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. *Nature Neuroscience*, 4, 233–234.
- Cao, X., & Sudhof, T. C. (2001). A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. *Science*, 293, 115–120.
- Capell, A., Steiner, H., Romig, H., Keck, S., Baader, M., Grim, M. G., et al. (2000). Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. *Nature Cell Biology*, 2, 205–211.
- Caughey, B., & Lansbury, P. T. (2003). Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. *Annual Review of Neuroscience*, 26, 267–298.
- Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. *Nature Neuroscience*, 2, 271–276.
- Chen, G., Chen, K. S., Knox, J., Inglis, J., Bernard, A., Martin, S. J., et al. (2000). A learning deficit related to age and b-amyloid plaques in a mouse model of Alzheimer's disease. *Nature*, 408, 975–979.
- Chow, V., Savonenko, A., Melnikova, T., Kim, H., Price, D., Li, T., et al. (2010a). Modeling an anti-amyloid combination therapy for Alzheimer's disease. Ref Type: Serial (Book, Monograph).
- Chow, V. W., Savonenko, A. V., Melnikova, T., Kim, H., Price, D. L., Li, T., et al. (2010).

- Modeling an anti-amyloid combination therapy for Alzheimer's disease. *Science Translational Medicine*, 2, 13ra1.
- Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., et al. (2003). *In vivo* assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. *The Journal of Neuroscience*, 23, 8844–8853.
- Citron, M. (2010). Alzheimer's disease: Strategies for disease modification. *Nature Reviews. Drug Discovery*, 9, 387–398.
- de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacskai, B. J., Spire-Jones, T. L., et al. (2010). Caspase activation precedes and leads to tangles. *Nature*, 464, 1201–1204.
- De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with presenilin generate an active gamma-secretase complex. *Neuron*, 38, 9–12.
- De Strooper, B., Annaert, W. G., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., et al. (1999). A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. *Nature*, 398, 518–522.
- DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002). Brain to plasma amyloid-beta efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. *Science*, 295, 2264–2267.
- Doan, A., Thinakaran, G., Borchelt, D. R., Slunt, H. H., Ratovitski, T., Podlisny, M., et al. (1996). Protein topology of presenilin 1. *Neuron*, 17, 1023–1030.
- Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., et al. (2002). Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. *Nature Neuroscience*

- Edbauer, D., Winkler, E., Haass, C., & Steiner, H. (2002). Presenilin and nicastrin regulate each other and determine amyloid beta- peptide production via complex formation. *Proceedings of the National Academy of Sciences of the United States of America*, *99*, 8666–8671.
- Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J. Y., et al. (2000). Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. *Nature Cell Biology*, *2*, 428–434.
- Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Ye, W., Diehl, T. S., Selkoe, D. J., et al. (2002). Activity-dependent isolation of the presenilin- γ -secretase complex reveals nicastrin and a γ substrate. *Proceedings of the National Academy of Sciences*, *14*, 1–6.
- Farzan, M., Schnitzler, C. E., Vasilieva, N., Leung, D., & Choe, H. (2000). BACE2, a β -secretase homolog, cleaves at the β site and within the amyloid- β region of the amyloid- β precursor protein. *Proceedings of the National Academy of Sciences*, *97*, 9712–9717.
- Frisardi, V., Solfrizzi, V., Imbimbo, P. B., Capurso, C., D’Introno, A., Colacicco, A. M., et al. (2010). Towards disease-modifying treatment of Alzheimer’s disease: Drugs targeting beta-amyloid. *Current Alzheimer Research*, *7*, 40–55.
- Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., et al. (2003). Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer’s disease. *Proceedings of the National Academy of Sciences of the United States of America*, *100*, 10032–10037.
- Ghaemmaghani, S., Ullman, J., Ahn, M., St, Martin, S., & Prusiner, S. B. (2010). Chemical induction of misfolded prion protein conformers in cell culture. *The Journal of Biological Chemistry*, *285*, 10415–10423.

- Goedert, M., & Spillantini, M. -G. (2006). Neurodegenerative alpha-Synucleinopathies and tauopathies Siegel Albers Brady Price (Eds.), *Basic neurochemistry: Molecular, cellular, and medical aspects* (pp. 745–759) (7th ed.). Elsevier.
- Golde, T. E., Schneider, L. S., & Koo, E. H. (2011). Anti- β therapeutics in Alzheimer's disease: The need for a paradigm shift. *Neuron*, *69*, 203–213.
- Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., et al. (2003). Alzheimer's disease-affected brain: Presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proceedings of the National Academy of Sciences of the United States of America*, *100*, 10417–10422.
- Gotz, J., Chen, F., Van Dorpe, J., & Nitsch, R. M. (2001). Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by A β fibrils. *Science*, *293*, 1491–1495.
- Gotz, J., & Ittner, L. M. (2008). Animal models of Alzheimer's disease and frontotemporal dementia. *Nature Reviews. Neuroscience*, *9*, 532–544.
- Goutte, C., Tsunozaki, M., Hale, V. A., & Priess, J. R. (2002). APH-1 is a multipass membrane protein essential for the Notch signaling pathway in *Caenorhabditis elegans* embryos. *Proceedings of the National Academy of Sciences of the United States of America*, *99*, 775–779.
- Haass, C. (2004). Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid β -peptide generation. *The EMBO Journal*, *23*, 483–488.
- Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., et al. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nature Genetics*, *41*, 1088–1093.
- Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A., Rulicke, T.,

- et al. (2000). Mice with combined gene knock-outs reveal essential and partially redundant functions of amyloid precursor protein family members. *The Journal of Neuroscience*, *20*, 7951–7963.
- Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G. Q., Tatsuno, G., Hu, K., et al. (1999). Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. *Proceedings of the National Academy of Sciences*, *96*, 3228–3233.
- Iwatsubo, T. (2004). The gamma-secretase complex: Machinery for intramembrane proteolysis. *Current Opinion in Neurobiology*, *14*, 379–383.
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). *Neuron*, *13*, 45–53.
- Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide *in vivo*: Evidence for augmentation of a 42-specific gamma secretase. *Human Molecular Genetics*, *13*, 159–170.
- Jankowsky, J. L., Slunt, H. H., Gonzales, V., Savonenko, A. V., Wen, J. C., Jenkins, N. A., et al. (2005). Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. *PLoS Medicine*, *2*, e355.
- Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., et al. (2003). APP processing and synaptic function. *Neuron*, *37*, 925–937.
- Khlistunova, I., Biernat, J., Wang, Y. P., Pickhardt, M., von Bergen, M., Gazova, Z., et al. (2006). Inducible expression of tau repeat domain in cell models of tauopathy—

- aggregation is toxic to cells but can be reversed by inhibitor drugs. *Journal of Biological Chemistry*, 281, 1205–1214.
- Kim, J., Basak, J. M., & Holtzman, D. M. (2009a). The role of apolipoprotein E in Alzheimer's disease. *Neuron*, 63, 287–303.
- Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., et al. (2009b). Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. *Neuron*, 64, 632–644.
- Kistner, A., Gossen, M., Zimmermann, F., Jerecic, J., Ullmer, C., Lubbert, H., et al. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*, 93, 10933–10938.
- Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomstrand, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer's disease using the novel positron emission tomography tracer, Pittsburgh Compound-B. *Annals of Neurology*, 55, 1–14.
- Koo, E. H., & Kopan, R. (2004). Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. *Nature Medicine*, 10(Suppl.), S26–S33.
- Koo, E. H., Sisodia, S. S., Archer, D. R., Martin, L. J., Weidemann, A., Beyreuther, K. T., et al. (1990). Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. *Proceedings of the National Academy of Sciences*, 87, 1561–1565.
- Kotilinek, L. A., Bacskai, B. J., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., et al. (2002). Reversible memory loss in a mouse transgenic model of Alzheimer's disease. *The Journal of Neuroscience*, 22, 6331–6335.

- Kounnas, M. Z., Danks, A. M., Cheng, S., Tyree, C., Ackerman, E., Zhang, X., et al. (2010). Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. *Neuron*, *67*, 769–780.
- Lee, V. M., Goedert, M., & Trojanowski, J. Q. (2001). Neurodegenerative tauopathies. *Annual Review of Neuroscience*, *24*, 1121–1159.
- Lewis, J., Dickson, D. W., Lin, W. -L., Chisholm, L., Corral, A., Jones, G., et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science*, *293*, 1487–1491.
- Li, R., Lindholm, K., Yang, L. B., Yue, X., Citron, M., Yan, R., et al. (2004). Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, *101*, 3632–3637.
- Li, T., Ma, G., Cai, H., Price, D. L., & Wong, P. C. (2003). Nicastrin is required for assembly of presenilin/gamma-secretase complexes to mediate Notch signaling and for processing and trafficking of beta-amyloid precursor protein in mammals. *The Journal of Neuroscience*, *23*, 3272–3277.
- Li, Y. M., Xu, M., Lai, M. T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., et al. (2000). Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. *Nature*, *405*, 689–694.
- Liu, Y., Yoo, M. J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., et al. (2008). Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. *The Journal of Neuroscience*, *28*, 13805–13814.

- Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. *The American Journal of Pathology*, *155*, 853–862.
- Luo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., et al. (2001). Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. *Nature Neuroscience*, *4*, 231–232.
- Ma, G., Li, T., Price, D. L., & Wong, P. C. (2005). APH-1a is the principal mammalian APH-1 isoform present in gamma-secretase complexes during embryonic development. *The Journal of Neuroscience*, *25*, 192–198.
- Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. *The Journal of Neuroscience*, *27*, 10957–10968.
- Marjaux, E., Hartmann, D., & De Strooper, B. (2004). Presenilins in memory, Alzheimer's disease, and therapy. *Neuron*, *42*, 189–192.
- McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS–ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. *Neurology*, *34*, 939–944.
- Monsonogo, A., & Weiner, H. L. (2003). Immunotherapeutic approaches to Alzheimer's disease. *Science*, *302*, 834–838.
- Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., et al. (2000). Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

Nature, 408, 982–985.

Morris, J. C., & Price, J. L. (2001a). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. *Journal of Molecular Neuroscience*, 17, 101–118.

Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., et al. (2001b). Mild cognitive impairment represents early-stage Alzheimer disease. *Archives of Neurology*, 58, 397–405.

Naruse, S., Thinakaran, G., Luo, J. J., Kusiak, J. W., Tomita, T., Iwatsubo, T., et al. (1998). Effects of PS1 deficiency on membrane protein trafficking in neurons. *Neuron*, 21, 1213–1221.

Nestor, P. J., Scheltens, P., & Hodges, J. R. (2004). Advances in the early detection of Alzheimer's disease. *Nature Medicine*, 10(Suppl.), S34–S41.

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kaye, R., et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular A β and synaptic dysfunction. *Neuron*, 39, 409–421.

Ohno, M., Sametsky, E. A., Younkin, L. H., Oakley, H., Younkin, S. G., Citron, M., et al. (2004). BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. *Neuron*, 41, 27–33.

Perrin, R. J., Fagan, A. M., & Holtzman, D. M. (2009). Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. *Nature*, 461, 916–922.

Petersen, R. C. (2003). Mild cognitive impairment clinical trials. *Nature Reviews. Drug Discovery*, 2, 646–653.

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., et al. (2001).

- Current concepts in mild cognitive impairment. *Archives of Neurology*, 58, 1985–1992.
- Price, D. L., & Sisodia, S. S. (1998a). Mutant genes in familial Alzheimer's disease and transgenic models. *Annual Review of Neuroscience*, 21, 479–505.
- Price, D. L., Tanzi, R. E., Borchelt, D. R., & Sisodia, S. S. (1998b). Alzheimer's disease: Genetic studies and transgenic models. *Annual Review of Genetics*, 32, 461–493.
- Querfurth, H. W., & LaFerla, F. M. (2010). Alzheimer's disease. *The New England Journal of Medicine*, 362, 329–344.
- Reddy, M. M., Wilson, R., Wilson, J., Connell, S., Gocke, A., Hynan, L., et al. (2011). Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. *Cell*, 144, 132–142.
- Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., et al. (2007). The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nature Genetics*, 39, 168–177.
- Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., et al. (2011). Clearance of amyloid by circulating lipoprotein receptors. *Nature Medicine*, 1029–1031.
- Savonenko, A. V., Melnikova, T., Laird, F. M., Stewart, K. A., Price, D. L., & Wong, P. C. (2008). Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. *Proceedings of the National Academy of Sciences of the United States of America*, 105, 5585–5590.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. *Nature*, 400, 173–177.
- Selkoe, D., & Kopan, R. (2003). Notch and presenilin: Regulated intramembrane proteolysis

- links development and degeneration. *Annual Review of Neuroscience*, 26, 565–597.
- Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. *Science*, 298, 789–791.
- Shen, J., Bronson, R. T., Chen, D. F., Xia, W., Selkoe, D. J., & Tonegawa, S. (1997). Skeletal and CNS defects in presenilin-1-deficient mice. *Cell*, 89, 629–639.
- Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature*, 375, 754–760.
- Sisodia, S. S., & George-Hyslop, P. H. (2002). gamma-Secretase, Notch, Abeta and Alzheimer's disease: Where do the presenilins fit in?. *Nature Reviews. Neuroscience*, 3, 281–290.
- Sisodia, S. S., Koo, E. H., Beyreuther, K. T., Unterbeck, A., & Price, D. L. (1990). Evidence that b-amyloid protein in Alzheimer's disease is not derived by normal processing. *Science*, 248, 492–495.
- Sisodia, S. S., Koo, E. H., Hoffman, P. N., Perry, G., & Price, D. L. (1993). Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. *The Journal of Neuroscience*, 13, 3136–3142.
- Sperling, R. A., Laviolette, P. S., O'Keefe, K., O'Brien, J., Rentz, D. M., Pihlajamaki, M., et al. (2009). Amyloid deposition is associated with impaired default network function in older persons without dementia. *Neuron*, 63, 178–188.
- Steiner, H., Winkler, E., Edbauer, D., Prokop, S., Basset, G., Yamasaki, A., et al. (2002). PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin. *The Journal of Biological Chemistry*, 277, 39062–39065.
- Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K. H., Mistl, C., Rothacher, S., et

- al. (1997). Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. *Proceedings of the National Academy of Sciences*, *94*, 13287–13292.
- Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., et al. (2003). Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. *JAMA: The Journal of the American Medical Association*, *289*, 2094–2103.
- Takasugi, N., Tomita, T., Hayashi, I., Tsuruoka, M., Niimura, M., Takahashi, Y., et al. (2003). The role of presenilin cofactors in the gamma-secretase complex. *Nature*, *422*, 438–441.
- Thinakaran, G., Harris, C. L., Ratovitski, T., Davenport, F., Slunt, H. H., Price, D. L., et al. (1997). Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. *The Journal of Biological Chemistry*, *272*, 28415–28422.
- Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999). b-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*, *286*, 735–741.
- Vassar, R., Kovacs, D. M., Yan, R., & Wong, P. C. (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: Regulation, cell biology, function, and therapeutic potential. *The Journal of Neuroscience*, *29*, 12787–12794.
- Walsh, D. M., & Selkoe, D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. *Neuron*, *44*, 181–193.
- Wang, Y., Garg, S., Mandelkow, E. M., & Mandelkow, E. (2010). Proteolytic processing of tau. *Biochemical Society Transactions*, *38*, 955–961.

- Wang, Y. P., Biernat, J., Pickhardt, M., Mandelkow, E., & Mandelkow, E. M. (2007). Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. *Proceedings of the National Academy of Sciences of the United States of America*, *104*, 10252–10257.
- Wengenack, T. M., Reyes, D. A., Curran, G. L., Borowski, B. J., Lin, J., Preboske, G. M., et al. (2011). Regional differences in MRI detection of amyloid plaques in AD transgenic mouse brain. *Neuroimage*, *54*, 113–122.
- Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981). Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. *Annals of Neurology*, *10*, 122–126.
- Wolfe, M. S. (2002). Therapeutic strategies for Alzheimer's disease. *Nature Reviews. Drug Discovery*, *1*, 859–866.
- Wong, P. C., Cai, H., Borchelt, D. R., & Price, D. L. (2002). Genetically engineered mouse models of neurodegenerative diseases. *Nature Neuroscience*, *5*, 633–639.
- Wong, P. C., Price, D. L., & Cai, H. (2001). The brain's susceptibility to amyloid plaques. *Science*, *293*, 1434–1435.
- Wong, P. C., Zheng, H., Chen, H., Becher, M. W., Sirinathsinghji, D. J., Trumbauer, M. E., et al. (1997). Presenilin 1 is required for Notch1 and Dll1 expression in the paraxial mesoderm. *Nature*, *387*, 288–292.
- Xia, P., Chen, H. S., Zhang, D., & Lipton, S. A. (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. *The Journal of Neuroscience*, *30*, 11246–11250.
- Yan, R., Bienkowski, M. J., Shuck, M. E., Miao, H., Tory, M. C., Pauley, A. M., et al. (1999).

Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity.
Nature, 402, 533–537.

Yang, L. B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X. L., et al. (2003). Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease.
Nature Medicine, 9, 3–4.

Zhang, D., & Raichle, M. E. (2010). Disease and the brain's dark energy. *Nature Reviews Neurology*, 6, 15–28.